Investigational Drug Information for Balovaptan
What is the drug development status for Balovaptan?
Balovaptan is an investigational drug.
There have been 12 clinical trials for Balovaptan.
The most recent clinical trial was a Phase 1 trial, which was initiated on August 8th 2018.
The most common disease conditions in clinical trials are Autism Spectrum Disorder, Disease, and Child Development Disorders, Pervasive. The leading clinical trial sponsors are Hoffmann-La Roche and [disabled in preview].
There are twenty US patents protecting this investigational drug.
Summary for Balovaptan
| US Patents | 20 |
| International Patents | 0 |
| US Patent Applications | 45 |
| WIPO Patent Applications | 10 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 1 (2018-08-08) |
| Vendors | 39 |
Recent Clinical Trials for Balovaptan
| Title | Sponsor | Phase |
|---|---|---|
| The Effect of Hepatic Impairment on the Pharmacokinetics of Balovaptan | Hoffmann-La Roche | Phase 1 |
| Study to Evaluate The Safety and Efficacy of Balovaptan in Participants With Acute Ischemic Stroke at High Risk of Developing Malignant Brain Edema | Hoffmann-La Roche | Phase 2 |
| Study To Evaluate The Efficacy And Safety Of Balovaptan In Adults With Post-Traumatic Stress Disorder (PTSD) | Hoffmann-La Roche | Phase 2 |
Clinical Trial Summary for Balovaptan
Top disease conditions for Balovaptan
Top clinical trial sponsors for Balovaptan
US Patents for Balovaptan
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Balovaptan | ⤷ Start Trial | Synthesis of trans-8-chloro-5-methyl-1-[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10B-tetraaza-benzo[E]azulene and crytalline forms thereof | Hoffmann La Roche Inc | ⤷ Start Trial |
| Balovaptan | ⤷ Start Trial | V1A antagonists to treat phase shift sleep disorders | Hoffmann La Roche Inc | ⤷ Start Trial |
| Balovaptan | ⤷ Start Trial | Synthesis of trans-8-chloro-5-methyl-1-[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10B-tetraaza-benzo[e]azulene and crytalline forms thereof | Hoffmann La Roche Inc | ⤷ Start Trial |
| Balovaptan | ⤷ Start Trial | Triazolobenzazepines as vasopressin V1a receptor antagonists | Richter Gedeon Nyrt | ⤷ Start Trial |
| Balovaptan | ⤷ Start Trial | Compositions and methods for treating anxiety-related disorders | Yamo Pharmaceuticals LLC | ⤷ Start Trial |
| Balovaptan | ⤷ Start Trial | Regulated biocircuit systems | Obsidian Therapeutics Inc | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
